About US

Company Profile

President Message

Our Challenge

Pharmaceuticals created by the diligent efforts of humans working for progress in medical science save the lives of countless people and help people lead healthy lives, but there are still unmet medical needs and many diseases for which effective treatments do not exist—this is the reality of medicine today. Even now, at this very moment, there are people waiting for innovative new drugs to be discovered and developed. We think of them constantly, and it is for them that we strive to develop and deliver new drugs as quickly as possible—this is the challenge we take on every single day.

Daiichi Sankyo RD Novare was established in 2011 as a common platform supporting the global R&D activities of the entire Daiichi Sankyo Group. This unique business model will revolutionize how drugs are discovered and developed. Our mission is to implement both therapeutic-area-independent innovative technologies for early-stage drug discovery and high-quality streamlined processes for clinical development.

The drug discovery research division is actively looking for potential opportunities for new exploratory research. We are also pursuing increases in efficiency by using advanced technologies developed internally and externally through the framework of open innovation. Our efforts are focused specifically on improving the probability of success in acquiring “validated hits”1 and being recognized as a Center of Excellence for biomarker research. To achieve these goals, we believe it is essential to integrate processes, from target identification and validation to hit-compound acquisition via high-throughput screening and biological assessments.

In April 2018, we newly created the translational research division to enhance capability and capacity in clinical biomarker research. Consequently, we are actively supporting the Daiichi Sankyo 2025 vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology.”

The development division conducts a range of clinical trials; in these trials we are convinced it is critical to harmonize the rights, welfare, and safety of subjects with the quality and reliability of the scientific data obtained. In the domestic clinical testing, after proof-of-concept2 acquisition we intend to provide a comprehensive and value-added service as a package, covering development-related activities on contract through process innovation.

Pioneering the Future

The key to creating groundbreaking new drugs lies in how basic technologies are combined and used. With one technology alone, even if it is innovative, it is impossible to create innovative drugs. We believe that drug development starts with knowing what occurs on the frontlines of medicine and grasping the true needs of patients and physicians.

The name “Novare” comes from the Latin word for “to change, to renew.” We offer new proposals for pharmaceutical research and development processes and, at the same time, continue the challenge of creating innovative new drugs as a partner truly trusted by those around us, with an awareness of the pride and responsibility this entails. We do work that is worthy of this challenge and provide a place that awakens the desire to take it on. We seek associates with a strong desire to continue polishing that one grain of ore—through curiosity, compassion, passion, and ingenuity—that will save others, and with the ability to passionately convey new values.

Hidemi Masumura PhD
President and Representative Director

 

Notes:
*1) Prototype compounds that interaction with the target molecule and are suitable for structural optimization in terms of efficacy, kinetics, and physical properties
*2) Proof of a drug’s efficacy